Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
16 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/16/2982367/0/en/Anthos-Therapeutics-Shares-New-Analysis-from-the-Landmark-AZALEA-TIMI-71-Study-Demonstrating-the-Factor-XI-Inhibitor-Abelacimab-Substantially-Reduced-Bleeding-in-Patients-on-Antipl.html
31 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/31/2972543/0/en/Anthos-Therapeutics-Appoints-Will-Kane-as-President-and-Chief-Commercial-Officer-and-Venkat-Ramanan-as-Chief-Financial-Officer.html
10 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/10/2961258/0/en/Anthos-Therapeutics-Appoints-Mia-Kelley-as-General-Counsel-and-Laurel-Ostrom-as-Chief-Human-Resources-Officer.html
02 Sep 2024
// BUSINESSWIRE
06 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/06/2894638/0/en/Anthos-Therapeutics-Announces-84-of-Eligible-Patients-Have-Transitioned-to-Abelacimab-in-the-AZALEA-TIMI-71-Extension-Study-of-Atrial-Fibrillation-Patients-at-a-Moderate-to-High-Ri.html
06 May 2024
// BUSINESSWIRE
Details:
MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2024
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anthos Therapeutics Shares New Data on Abelacimab's Low Bleeding Risk
Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 02, 2024
Details:
MAA868 (abelacimab) is a highly selective, monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition, in patients with Atrial Fibrillation.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2024
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anthos Announces 84% Transition to Abelacimab in AZALEA-TIMI 71 Study for AFib at a Stroke
Details : MAA868 (abelacimab) is a highly selective, monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition, in patients with Atrial Fibrillation.
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 06, 2024
Details:
MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 13, 2023
Details:
MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Memphis Seniors with a History of Atrial Fibrillation Joining New Research Study
Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 20, 2023
Details:
MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition, which is investigated for patients with atrial fibrillation at moderate-to-high risk of stroke.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition, which is investigated for patients with atrial fibrillation at moderate-to-high risk ...
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 18, 2023
Details:
MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Itreas
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Itreas
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 08, 2023
Details:
MAA868 (Abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. It has received FDA Fast-Track Designations for the prevention systemic embolism with atrial fibrillation.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MAA868 (Abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. It has received FDA Fast-Track Designations for the prevention systemic embolism with...
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 03, 2023
Details:
MAA868 (abelacimab) is dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity, targets active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MAA868 (abelacimab) is dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity, targets active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activ...
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 25, 2022
Details:
Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab
Details : Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 13, 2022
Details:
MAA868 (abelacimab) is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
Details : MAA868 (abelacimab) is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Brand Name : MAA868
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 05, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?